Zacks Investment Research Lowers Athersys Inc. (ATHX) to Hold

Zacks Investment Research Lowers Athersys Inc. (ATHX) to Hold


According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity.



from Biotech News